Literature DB >> 8680123

Extreme hyperbilirubinemia induced by endoscopic injection sclerotherapy in a patient with esophageal varices and thalassemia: report of a case.

K Nishioka1, M Hashizume, S Kitano, M Ohta, K Ueno, M Tomikawa, H Higashi, T Okamura, K Sugimachi.   

Abstract

We describe herein the case of a 57-year-old man with thalassemia who developed acute liver failure after undergoing endoscopic injection sclerotherapy (EIS) to control hemorrhage from a ruptured esophageal varix. The patient, who had been confirmed as having liver cirrhosis due to chronic hepatitis C with thalassemia in 1989, was admitted to our department to undergo EIS for esophageal varices, at which time his serum total bilirubin level was 5.5 mg/dl. As a small amount of hematemesis occurred just after a percutaneous transhepatic portography was performed, emergency EIS was carried out, following which the serum total bilirubin level markedly increased, mainly with a direct fraction, until it reached 70 mg/dl. The patient eventually died from acute liver failure with extreme hyperbilirubinemia on the 27th day after experiencing hematemesis despite all treatment. This unfortunate case demonstrates that sclerotherapy could be an inappropriate method of treatment for patients with hemolytic disease.

Entities:  

Mesh:

Year:  1996        PMID: 8680123     DOI: 10.1007/bf00311993

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  13 in total

1.  AN UNUSUAL HEPATIC SEQUELA OF SICKLE CELL ANEMIA: A REPORT OF FIVE CASES.

Authors:  D M OWEN; J E ALDRIDGE; R B THOMPSON
Journal:  Am J Med Sci       Date:  1965-02       Impact factor: 2.378

2.  Sickle cell crisis resembling obstructive (cholangiolar type) jaundice. Report of a case and review of the literature.

Authors:  F A WADE
Journal:  Va Med Mon (1918)       Date:  1960-09

3.  Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices.

Authors:  G V Stiegmann; J S Goff; P A Michaletz-Onody; J Korula; D Lieberman; Z A Saeed; R M Reveille; J H Sun; S R Lowenstein
Journal:  N Engl J Med       Date:  1992-06-04       Impact factor: 91.245

4.  Sickle cell hepatopathy.

Authors:  T W Sheehy
Journal:  South Med J       Date:  1977-05       Impact factor: 0.954

5.  Endoscopic injection sclerotherapy for 1,000 patients with esophageal varices: a nine-year prospective study.

Authors:  M Hashizume; S Kitano; N Koyanagi; K Tanoue; M Ohta; H Wada; H Yamaga; H Higashi; Y Iso; T Iwanaga
Journal:  Hepatology       Date:  1992-01       Impact factor: 17.425

6.  Haptoglobin to protect against renal damage from ethanolamine oleate sclerosant.

Authors:  M Hashizume; S Kitano; H Yamaga; K Sugimachi
Journal:  Lancet       Date:  1988-08-06       Impact factor: 79.321

7.  Bland cholestasis. Unusual hepatic sequela in sickle cell anemia.

Authors:  M Krishnamurthy; A Elguezabal; C K Lee; H Dosik
Journal:  Postgrad Med       Date:  1978-09       Impact factor: 3.840

8.  Acute cholestatic jaundice in children with sickle cell disease: hepatic crises or hepatitis?

Authors:  A A Mallouh; M I Asha
Journal:  Pediatr Infect Dis J       Date:  1988-10       Impact factor: 2.129

Review 9.  Hepatobiliary system in sickle cell disease.

Authors:  T T Schubert
Journal:  Gastroenterology       Date:  1986-06       Impact factor: 22.682

10.  Ischemic hepatitis.

Authors:  T E Bynum; J K Boitnott; W C Maddrey
Journal:  Dig Dis Sci       Date:  1979-02       Impact factor: 3.199

View more
  1 in total

1.  Endoscopic injection sclerotherapy improves liver function compared with endoscopic variceal ligation.

Authors:  Tsuguru Hayashi; Tatsuyuki Watanabe; Michihiko Shibata; Shinsuke Kumei; Shinji Oe; Koichiro Miyagawa; Yuichi Honma; Masaru Harada
Journal:  Sci Rep       Date:  2021-10-14       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.